Oncology
Metastatic Cancer
1
Pipeline Programs↗
28
Active Trials↗
31
Companies Involved↗
Metastatic Cancer is an early-stage landscape with 1 program across 31 companies. The most active players are Takeda, Eli Lilly, Roche.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
2programs
Small molecule150%
Monoclonal antibody150%
Modality classified for 100% of 2 pipeline programs.
Analysis
Trial Status
137
clinical trials
Completed71 · 52%
Terminated21 · 15%
Recruiting19 · 14%
Unknown status9 · 7%
Active, not recruiting7 · 5%
Withdrawn4 · 3%
Other6 · 4%
Clinical Trials
Trial Activity
137 trials
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
Recruiting·—·Phase 1·NCT05065736·4 enrolled
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
Recruiting·—·Phase 1·NCT07192900·10 enrolled
Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
Recruiting·—·Phase 1·NCT06016179·12 enrolled
Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer
Recruiting·—·Phase 1·NCT05232409·72 enrolled
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)